Brief: Galera Reports Q1 2023 Financial Results And Recent Corporate Updates
May 11 (Reuters) - Galera Therapeutics Inc GRTX.O :
* GALERA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
RECENT
CORPORATE UPDATES
* Q1 LOSS PER SHARE $0.50
* GALERA THERAPEUTICS- AVASOPASEM NDA GRANTED FDA PRIORITY
REVIEW
FOR RADIOTHERAPY-INDUCED SEVERE ORAL MUCOSITIS; PDUFA TARGET
DATE OF AUGUST 9, 2023
* AS OF MARCH 31, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS OF $47.8 MILLION
* Q1 EARNINGS PER SHARE VIEW $-0.38 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1cL7XH
Further company coverage: GRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement